Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08YVP
|
|||
| Former ID |
DIB001662
|
|||
| Drug Name |
Vericigiuat
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 2 | [1] | |
| Company |
Bayer healthcare pharmaceutical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Guanylate cyclase soluble beta-1 (GUCY1B1) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| Vascular smooth muscle contraction | ||||
| Gap junction | ||||
| Platelet activation | ||||
| Circadian entrainment | ||||
| Long-term depression | ||||
| Oxytocin signaling pathway | ||||
| Salivary secretion | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| Panther Pathway | Endothelin signaling pathway | |||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | Nitric oxide stimulates guanylate cyclase | |||
| WikiPathways | Platelet homeostasis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Bayer HealthCare Pharmaceuticals. | |||
| REF 2 | Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026-38. | |||
| REF 3 | Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279-313. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.